Cargando…
Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study
BACKGROUND: The management of the COVID-19 pandemic is hampered by long delays associated with centralised laboratory PCR testing. In hospitals, these delays lead to poor patient flow and nosocomial transmission. Rapid, accurate tests are therefore urgently needed in preparation for the next wave of...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544498/ https://www.ncbi.nlm.nih.gov/pubmed/33038974 http://dx.doi.org/10.1016/S2213-2600(20)30454-9 |
_version_ | 1783591867700477952 |
---|---|
author | Brendish, Nathan J Poole, Stephen Naidu, Vasanth V Mansbridge, Christopher T Norton, Nicholas J Wheeler, Helen Presland, Laura Kidd, Stephen Cortes, Nicholas J Borca, Florina Phan, Hang Babbage, Gavin Visseaux, Benoit Ewings, Sean Clark, Tristan W |
author_facet | Brendish, Nathan J Poole, Stephen Naidu, Vasanth V Mansbridge, Christopher T Norton, Nicholas J Wheeler, Helen Presland, Laura Kidd, Stephen Cortes, Nicholas J Borca, Florina Phan, Hang Babbage, Gavin Visseaux, Benoit Ewings, Sean Clark, Tristan W |
author_sort | Brendish, Nathan J |
collection | PubMed |
description | BACKGROUND: The management of the COVID-19 pandemic is hampered by long delays associated with centralised laboratory PCR testing. In hospitals, these delays lead to poor patient flow and nosocomial transmission. Rapid, accurate tests are therefore urgently needed in preparation for the next wave of the pandemic. METHODS: We did a prospective, interventional, non-randomised, controlled study of molecular point-of-care testing in patients aged 18 years or older presenting with suspected COVID-19 to the emergency department or other acute areas of Southampton General Hospital during the first wave of the pandemic in the UK. Nose and throat swab samples taken at admission from patients in the point-of-care testing group were tested with the QIAstat-Dx Respiratory SARS-CoV-2 Panel. Samples taken from patients in a contemporaneous control group were tested by laboratory PCR. The primary outcome was time to results in the full cohort. This study is registered with ISRCTN (ISRCTN14966673) and is completed. FINDINGS: Between March 20 and April 29, 2020, 517 patients were assessed for eligibility, of whom 499 were recruited to the point-of-care testing group and tested by the QIAstat-Dx Respiratory SARS-CoV-2 Panel. 555 contemporaneously identified patients were included in the control group and tested by laboratory PCR. The two groups were similar with regard to the distribution of sex, age, and ethnicity. 197 (39%) patients in the point-of-care testing group and 155 (28%) in the control group tested positive for COVID-19 (difference 11·5% [95% CI 5·8–17·2], p=0·0001). Median time to results was 1·7 h (IQR 1·6–1·9) in the point-of-care testing group and 21·3 h (16·0–27·9) in the control group (difference 19·6 h [19·0–20·3], p<0·0001). A Cox proportional hazards regression model controlling for age, sex, time of presentation, and severity of illness also showed that time to results was significantly shorter in the point-of-care testing group than in the control group (hazard ratio 4023 [95% CI 545–29 696], p<0·0001). INTERPRETATION: Point-of-care testing is associated with large reductions in time to results and could lead to improvements in infection control measures and patient flow compared with centralised laboratory PCR testing. FUNDING: University Hospitals Southampton NHS Foundation Trust. |
format | Online Article Text |
id | pubmed-7544498 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75444982020-10-09 Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study Brendish, Nathan J Poole, Stephen Naidu, Vasanth V Mansbridge, Christopher T Norton, Nicholas J Wheeler, Helen Presland, Laura Kidd, Stephen Cortes, Nicholas J Borca, Florina Phan, Hang Babbage, Gavin Visseaux, Benoit Ewings, Sean Clark, Tristan W Lancet Respir Med Articles BACKGROUND: The management of the COVID-19 pandemic is hampered by long delays associated with centralised laboratory PCR testing. In hospitals, these delays lead to poor patient flow and nosocomial transmission. Rapid, accurate tests are therefore urgently needed in preparation for the next wave of the pandemic. METHODS: We did a prospective, interventional, non-randomised, controlled study of molecular point-of-care testing in patients aged 18 years or older presenting with suspected COVID-19 to the emergency department or other acute areas of Southampton General Hospital during the first wave of the pandemic in the UK. Nose and throat swab samples taken at admission from patients in the point-of-care testing group were tested with the QIAstat-Dx Respiratory SARS-CoV-2 Panel. Samples taken from patients in a contemporaneous control group were tested by laboratory PCR. The primary outcome was time to results in the full cohort. This study is registered with ISRCTN (ISRCTN14966673) and is completed. FINDINGS: Between March 20 and April 29, 2020, 517 patients were assessed for eligibility, of whom 499 were recruited to the point-of-care testing group and tested by the QIAstat-Dx Respiratory SARS-CoV-2 Panel. 555 contemporaneously identified patients were included in the control group and tested by laboratory PCR. The two groups were similar with regard to the distribution of sex, age, and ethnicity. 197 (39%) patients in the point-of-care testing group and 155 (28%) in the control group tested positive for COVID-19 (difference 11·5% [95% CI 5·8–17·2], p=0·0001). Median time to results was 1·7 h (IQR 1·6–1·9) in the point-of-care testing group and 21·3 h (16·0–27·9) in the control group (difference 19·6 h [19·0–20·3], p<0·0001). A Cox proportional hazards regression model controlling for age, sex, time of presentation, and severity of illness also showed that time to results was significantly shorter in the point-of-care testing group than in the control group (hazard ratio 4023 [95% CI 545–29 696], p<0·0001). INTERPRETATION: Point-of-care testing is associated with large reductions in time to results and could lead to improvements in infection control measures and patient flow compared with centralised laboratory PCR testing. FUNDING: University Hospitals Southampton NHS Foundation Trust. Elsevier Ltd. 2020-12 2020-10-08 /pmc/articles/PMC7544498/ /pubmed/33038974 http://dx.doi.org/10.1016/S2213-2600(20)30454-9 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Articles Brendish, Nathan J Poole, Stephen Naidu, Vasanth V Mansbridge, Christopher T Norton, Nicholas J Wheeler, Helen Presland, Laura Kidd, Stephen Cortes, Nicholas J Borca, Florina Phan, Hang Babbage, Gavin Visseaux, Benoit Ewings, Sean Clark, Tristan W Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study |
title | Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study |
title_full | Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study |
title_fullStr | Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study |
title_full_unstemmed | Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study |
title_short | Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study |
title_sort | clinical impact of molecular point-of-care testing for suspected covid-19 in hospital (cov-19poc): a prospective, interventional, non-randomised, controlled study |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544498/ https://www.ncbi.nlm.nih.gov/pubmed/33038974 http://dx.doi.org/10.1016/S2213-2600(20)30454-9 |
work_keys_str_mv | AT brendishnathanj clinicalimpactofmolecularpointofcaretestingforsuspectedcovid19inhospitalcov19pocaprospectiveinterventionalnonrandomisedcontrolledstudy AT poolestephen clinicalimpactofmolecularpointofcaretestingforsuspectedcovid19inhospitalcov19pocaprospectiveinterventionalnonrandomisedcontrolledstudy AT naiduvasanthv clinicalimpactofmolecularpointofcaretestingforsuspectedcovid19inhospitalcov19pocaprospectiveinterventionalnonrandomisedcontrolledstudy AT mansbridgechristophert clinicalimpactofmolecularpointofcaretestingforsuspectedcovid19inhospitalcov19pocaprospectiveinterventionalnonrandomisedcontrolledstudy AT nortonnicholasj clinicalimpactofmolecularpointofcaretestingforsuspectedcovid19inhospitalcov19pocaprospectiveinterventionalnonrandomisedcontrolledstudy AT wheelerhelen clinicalimpactofmolecularpointofcaretestingforsuspectedcovid19inhospitalcov19pocaprospectiveinterventionalnonrandomisedcontrolledstudy AT preslandlaura clinicalimpactofmolecularpointofcaretestingforsuspectedcovid19inhospitalcov19pocaprospectiveinterventionalnonrandomisedcontrolledstudy AT kiddstephen clinicalimpactofmolecularpointofcaretestingforsuspectedcovid19inhospitalcov19pocaprospectiveinterventionalnonrandomisedcontrolledstudy AT cortesnicholasj clinicalimpactofmolecularpointofcaretestingforsuspectedcovid19inhospitalcov19pocaprospectiveinterventionalnonrandomisedcontrolledstudy AT borcaflorina clinicalimpactofmolecularpointofcaretestingforsuspectedcovid19inhospitalcov19pocaprospectiveinterventionalnonrandomisedcontrolledstudy AT phanhang clinicalimpactofmolecularpointofcaretestingforsuspectedcovid19inhospitalcov19pocaprospectiveinterventionalnonrandomisedcontrolledstudy AT babbagegavin clinicalimpactofmolecularpointofcaretestingforsuspectedcovid19inhospitalcov19pocaprospectiveinterventionalnonrandomisedcontrolledstudy AT visseauxbenoit clinicalimpactofmolecularpointofcaretestingforsuspectedcovid19inhospitalcov19pocaprospectiveinterventionalnonrandomisedcontrolledstudy AT ewingssean clinicalimpactofmolecularpointofcaretestingforsuspectedcovid19inhospitalcov19pocaprospectiveinterventionalnonrandomisedcontrolledstudy AT clarktristanw clinicalimpactofmolecularpointofcaretestingforsuspectedcovid19inhospitalcov19pocaprospectiveinterventionalnonrandomisedcontrolledstudy |